144 related articles for article (PubMed ID: 34530385)
1. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
[TBL] [Abstract][Full Text] [Related]
2. Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody.
Nigam S; McCarl L; Kumar R; Edinger RS; Kurland BF; Anderson CJ; Panigrahy A; Kohanbash G; Edwards WB
Mol Imaging Biol; 2020 Jun; 22(3):685-694. PubMed ID: 31529407
[TBL] [Abstract][Full Text] [Related]
3. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
[No Abstract] [Full Text] [Related]
4. Enhanced Theranostic Efficacy of
Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
[TBL] [Abstract][Full Text] [Related]
5. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
6. CD38-Targeted Theranostics of Lymphoma with
Kang L; Li C; Rosenkrans ZT; Huo N; Chen Z; Ehlerding EB; Huo Y; Ferreira CA; Barnhart TE; Engle JW; Wang R; Jiang D; Xu X; Cai W
Adv Sci (Weinh); 2021 May; 8(10):2001879. PubMed ID: 34026426
[TBL] [Abstract][Full Text] [Related]
7. Targeting Infiltrating Myeloid Cells in Gastric Cancer Using a Pretargeted Imaging Strategy Based on Bio-Orthogonal Diels-Alder Click Chemistry and Comparison with
Zhang Y; Lin Q; Wang T; Shi D; Fu Z; Si Z; Xu Z; Cheng Y; Shi H; Cheng D
Mol Pharm; 2022 Jan; 19(1):246-257. PubMed ID: 34816721
[TBL] [Abstract][Full Text] [Related]
8. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
[TBL] [Abstract][Full Text] [Related]
9. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
11.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
12. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
Kim JE; Patel MA; Mangraviti A; Kim ES; Theodros D; Velarde E; Liu A; Sankey EW; Tam A; Xu H; Mathios D; Jackson CM; Harris-Bookman S; Garzon-Muvdi T; Sheu M; Martin AM; Tyler BM; Tran PT; Ye X; Olivi A; Taube JM; Burger PC; Drake CG; Brem H; Pardoll DM; Lim M
Clin Cancer Res; 2017 Jan; 23(1):124-136. PubMed ID: 27358487
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors in Human Glioma Microenvironment.
Ghouzlani A; Kandoussi S; Tall M; Reddy KP; Rafii S; Badou A
Front Immunol; 2021; 12():679425. PubMed ID: 34305910
[TBL] [Abstract][Full Text] [Related]
15. Construction and Application of a PD-L1-Targeted Multimodal Diagnostic and Dual-Functional Theranostics Nanoprobe.
He C; Guo Y; Zhou N; Wang Z; Liu T; Xu X; Wang F; Zhu H; Yang Z; Yang X; Xia L
Int J Nanomedicine; 2024; 19():5479-5492. PubMed ID: 38863646
[TBL] [Abstract][Full Text] [Related]
16. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
[TBL] [Abstract][Full Text] [Related]
17. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
18. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
19. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
20. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
